Overview
Cengiz Akosman practices practicing medicine in Sancaktepe, Turkey.
His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC) and Lung Cancer.
He is actively involved in clinical research, co-authoring 13 peer reviewed articles.
Gender
Locations
Sancaktepe, Turkey
Maltepe, Turkey
Samsun, 55000, Turkey
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Cengiz Akosman
Is Cengiz Akosman a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Cengiz Akosman is classified as an Experienced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Cengiz Akosman participate in research or clinical trials?
Yes. Cengiz Akosman has published 13 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Cengiz Akosman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Lung CancerMr. Akosman isExperienced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)Mr. Akosman isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).